The use of intraperitoneal chemotherapy for gastric malignancies

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–477.
   PubMedGoogle Scholar
• Stomach cancer estimated incidence, mortality and prevalence, worldwide. GLOBOCAN. International Association of Cancer Registries. 2012.
   Google Scholar
• Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol. 2000;16:516–521.
   PubMed Web of Science ®Google Scholar
• Saladino E, Fleres F, Mazzeo C, et al. The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer. Anticancer Res. 2014;34(4):2019–2022.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastriccancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123–1131.
   PubMed Web of Science ®Google Scholar
• Goéré D, Gras-Chaput N, Aupérin A, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14:148.
   PubMedGoogle Scholar
• Spiliotis JD, Halkia EA, Efstathiou E. Peritoneal carcinomatosis 2011: it’s about time for chemosurgery. J Buon. 2011;16(3):400–408.
   PubMed Web of Science ®Google Scholar
• D’Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–816.
   PubMedGoogle Scholar
• Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:911–919.
   PubMed Web of Science ®Google Scholar
• Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;(12):347–353.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Gastric cancer. Version2. 2018. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
   Google Scholar
• Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14:301–316.
   PubMed Web of Science ®Google Scholar
• Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27–S37.
   PubMed Web of Science ®Google Scholar
• Pak LM, Coit DG, Eaton AA, et al. Percutaneous peritoneal lavage for the rapid staging of gastric and pancreatic cancer. Ann Surg Oncol. 2017;24:1174–1179.
   PubMed Web of Science ®Google Scholar
• Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332–4337.
   PubMed Web of Science ®Google Scholar
• Dahdaleh FS, Turaga KK. Evolving treatment strategies and outcomes in advancedgastric cancer with peritoneal metastasis. Surg Oncol Clin N Am. 2018;27(3):519–537.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Sako S, Wakama S, et al. History of peritoneal surface malignancy treatment in Japan. Indian J Surg Oncol. 2019;10(Suppl 1):3–11.
   PubMedGoogle Scholar
• Jayne D Molecular biology of peritoneal carcinomatosis. In: Ceelen WP, editor. Cancer treatment and research. US: Springer; 2007. p. 21–31.
   Google Scholar
• Yonemura Y, Canbay E, Liu Y, et al. Trans-lymphatic metastasis in peritoneal dissemination. J Gastroint Dig Syst. 2013;S12. DOI:10.4172/2161-069X.S12-007
   Google Scholar
• Sugarbaker PH. Observation concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: a multidisciplinary approach. Boston: Kluwar Academic Publisher; 1997. p. 79–100.
   Google Scholar
• Yonemura Y. Trans-lymphatic metastasis. In: Yonemura Y, editor. Atlas and principles of peritonectomy for peritoneal surface malignancy. Published by NPO to Support Peritoneal Surface Malignancy; Japan; 2012. p. 188–206.
   Google Scholar
• Bettendorf U. Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology. 1978;11(3):111–116.
   PubMed Web of Science ®Google Scholar
• Tsujimoto H, Takhashi T, Hagiwara A, et al. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labeled cells. Br J Cancer. 1995;71:468–472.
   PubMed Web of Science ®Google Scholar
• Shimotsuma M, Takahashi T, Kawata M, et al. Cellular subset of the milky spots in the human greater omentum. Cell Tissue Res. 1991;264:599–601.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–673.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–4997.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Shiozaki H, Elimova E, Slack RS, et al. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016;113:29–35.
   PubMed Web of Science ®Google Scholar
• Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17:3173–3180.
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–591.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–168.
   PubMed Web of Science ®Google Scholar
• Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol. 2014;20:3905–3915.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open label phase 3 trial. Lancet Oncol. 2013;14:490–499.
   PubMed Web of Science ®Google Scholar
• Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–3060.
   PubMed Web of Science ®Google Scholar
• Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–628.
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–2403.
   PubMed Web of Science ®Google Scholar
• Kim JG, Ryoo BY, Park YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:301–307.
   PubMed Web of Science ®Google Scholar
• Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989;7:1310–1317.
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004.
   PubMed Web of Science ®Google Scholar
• Baba H, Yamamoto M, Endo K, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–49.
   PubMedGoogle Scholar
• Shirao K, Boku N, Yamada Y, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43:972–980.
   PubMed Web of Science ®Google Scholar
• SH H, Shin YR, Roh SY, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16:290–300.
   PubMed Web of Science ®Google Scholar
• Tamura S, Miki H, Okada K, et al. Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. Gastric Cancer. 2010;13:101–108.
   PubMed Web of Science ®Google Scholar
• Ishizone S, Maruta F, Saito H, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy. 2006;52:301–307.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.
   PubMedGoogle Scholar
• Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433–42.
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.
   PubMedGoogle Scholar
• Markman M. Intraperitoneal antineoplastic drug delivery: rationaleand results. Lancet Oncol. 2003;4:277–283.
   PubMed Web of Science ®Google Scholar
• Macrì A, Fortugno A, Saladino E. Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol. 2011;3(12):169–174.
   PubMed Web of Science ®Google Scholar
• Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–869.
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–272.
   PubMed Web of Science ®Google Scholar
• De Simone M, Barone R, Vaira M, et al. Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosis. J Surg Oncol. 2003;82:138–140.
   PubMed Web of Science ®Google Scholar
• Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–796.
   PubMed Web of Science ®Google Scholar
• Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am. 2003;12:561–583.
   PubMedGoogle Scholar
• Deraco M, De Simone M, Rossi CR, et al. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res. 2003;22:41–45.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Baratti D, Younan R, et al. The delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol. 2008;98:217–219.
   PubMed Web of Science ®Google Scholar
• Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61(2):232–237.
   PubMed Web of Science ®Google Scholar
• Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 1994;73(8):2048–2052.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996;119(4):437–444.
   PubMed Web of Science ®Google Scholar
• Sayag-Beaujard AC, Francois Y, Glehen O, et al. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res. 1999;19(2B):1375–1382.
   PubMed Web of Science ®Google Scholar
• Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139(1):20–26.
   PubMedGoogle Scholar
• Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–1581.
   PubMed Web of Science ®Google Scholar
• Desiderio J, Chao J, Melstrom L, et al. The 30-year experience – a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1–14.
   PubMed Web of Science ®Google Scholar
• Bonnot PE, Piessen G, Pocard M, et al. CYTO-CHIP: cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a propensity-score analysis from BIG RENAPE and FREGAT working groups. J Clin Oncol. 2018;36:8.
   Web of Science ®Google Scholar
• Bonnot PE, Piessen G, Kepenekian V, et al. FREGAT and BIG-RENAPE networks. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–2040.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Arvieux C, et al. Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–2377.
   PubMed Web of Science ®Google Scholar
• Leiting JL, Grotz TE. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol. 2018;10(10):282–289.
   PubMed Web of Science ®Google Scholar
• Chia CS, You B, Decullier E, et al. BIG RENAPE Group. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971–1979.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85–97.
   PubMed Web of Science ®Google Scholar
• Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12–26.
   PubMed Web of Science ®Google Scholar
• Levine EA, Stewart JH, Russel GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943–953.
   PubMed Web of Science ®Google Scholar
• Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004;8(4):454–463.
   PubMedGoogle Scholar
• Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526.
   PubMed Web of Science ®Google Scholar
• Rihuete C, Manzanedo I, Pereira F, et al. Cytoreductive surgery combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805–1810.
   PubMed Web of Science ®Google Scholar
• Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.
   PubMed Web of Science ®Google Scholar
• Charite University B, Germany, Aid GC. Cytoreductive surgery (CRS) with/without HIPEC in gastric cancer with peritoneal carcinomatosis. 2014. Available from: https://clinicaltrials.gov/show/NCT02158988
   Google Scholar
• Grotz TE, Fournier KF, Mansfield PF. Patient selection for cytoreductive surgery. Surg Oncol Clin N Am. 2018;27(3):443–462.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79(5):884–891.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–671.
   PubMedGoogle Scholar
• Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–485.
   PubMed Web of Science ®Google Scholar
• Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric cancer treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–1152.
   PubMed Web of Science ®Google Scholar
• Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338–3344.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661–665.
   PubMed Web of Science ®Google Scholar
• Hao Y, Liu Y, Ishibashi H, et al. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis. Eur J Surg Oncol. 2019 Mar 9;45(8):1493–1497.
   Web of Science ®Google Scholar
• Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18:3726–3731.
   PubMedGoogle Scholar
• Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67–70.
   PubMed Web of Science ®Google Scholar
• McVie JG, Dikhoff T, Van der Heide J. Tissue concentration of platinum after intraperitoneal cisplatinum in patients (PTS). Proc Am Assoc Cancer Res. 1985;26:162.
   Google Scholar
• Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250(2):242–246.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep. 2018;20(8):62.
   PubMed Web of Science ®Google Scholar
• Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat. 2014;46(3):270–279.
   PubMed Web of Science ®Google Scholar
• Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–1482.
   PubMed Web of Science ®Google Scholar
• Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14(1):35–41.
   PubMed Web of Science ®Google Scholar
• Berthet B, Sugarbaker TA, Chang D, et al. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35(3):413–419.
   PubMed Web of Science ®Google Scholar
• Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial non-definitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (Abstract). Dis Colon Rectum. 2018;61(3):347–354.
   Google Scholar
• Solass W, Kerb R, Murdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–559.
   PubMedGoogle Scholar
• Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–373.
   PubMedGoogle Scholar
• Khomyakov V, Ryabov A, Ivanov A, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159–166.
   PubMed Web of Science ®Google Scholar
• Girshally R, Demtröder C, Albayrak N, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14:253.
   PubMed Web of Science ®Google Scholar
• Teixeira Farinha H, Grass F, Kefleyesus A, et al. Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract. 2017;4596176.
   PubMed Web of Science ®Google Scholar
• Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178–2183.
   PubMed Web of Science ®Google Scholar
• Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stageperitoneal metastasis treated with Pressurized IntraPeritonealAerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41:1379–1385.
   PubMed Web of Science ®Google Scholar
• Robella M, Vaira M, De Simone M. Safety and feasibility of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.
   PubMed Web of Science ®Google Scholar
• Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, single-center implementation and response evaluation of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1–11.
   Web of Science ®Google Scholar
• Rezniczek GA, Jüngst F, Jütte H, et al. Dynamic changes of tumor gene expression during repeated Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in women with peritoneal cancer. BMC Cancer. 2016;16:654.
   PubMed Web of Science ®Google Scholar
• Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e377.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38–42.
   PubMed Web of Science ®Google Scholar
• Fushida S, Kinoshita J, Kaji M, et al. Society for Study of Peritoneal Carcinomatosis in Gastric Cancer.Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265–1272.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354–3358.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Stein A, Ridwelski K, et al. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer. 2015;18:833–842.
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209–2221.
   PubMed Web of Science ®Google Scholar
• Seidl C, Zöckler C, Beck R, et al. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. Eur J Nucl Med Mol Imaging. 2011;38:312–322.
   PubMed Web of Science ®Google Scholar